ライフサイエンスコーパス: tumor marker

1 Calcitonin is the principal serum tumor marker.

2 ion, and that NSP5alpha3alpha may serve as a tumor marker.

3 nducible protein (PIP), is a specific breast tumor marker.

4 The CRD-BP might be a novel human tumor marker.

5 cer development and may serve as a potential tumor marker.

6 nosensor for detection of the serum level of tumor marker.

7 nosensing of prostate-specific antigen (PSA) tumor marker.

8 lar endothelial growth factor (VEGF165) as a tumor marker.

9 he trend of TgAb measurements as a surrogate tumor marker.

10 protein product has been considered a useful tumor marker.

11 apy (RLT) in comparison with the established tumor markers.

12 rker levels while controlling for additional tumor markers.

13 serotype 5 and the other binding to various tumor markers.

14 ed antigens (TAAs) were shown to be relevant tumor markers.

15 l, dilation of the main pancreatic duct, and tumor markers.

16 linical utility of prognostic and predictive tumor markers.

17 ugh sensitive, is nonspecific for particular tumor markers.

18 chanistically to the overexpression of other tumor markers.

19 the basis of clinical presentation and serum tumor markers.

20 f Notch1 pathway proteins and neuroendocrine tumor markers.

21 iagnosis and patient perspectives on bladder tumor markers.

22 sting the potential value of these miRNAs as tumor markers.

23 ase, histologic type, and elevation of serum tumor markers.

24 re overexpressed in cancer and serve as good tumor markers.

25 in cancer and are potential drug targets and tumor markers.

26 ontrols, suggests that they are novel breast tumor markers.

27 or marker elevation or (2) not detectable by tumor markers.

28 or the identification of clinically relevant tumor markers.

29 noassays for peptides, including polypeptide tumor markers.

30 omas and the development of new and specific tumor markers.

31 analyses of SAGE databases to identify novel tumor markers.

32 vels to normalize the distributions of these tumor markers.

33 cilitating the rapid identification of novel tumor markers.

34 plastic tissues can, in turn, identify novel tumor markers.

35 blood analysis and diagnosis based on cancer tumor markers.

36 five principal groups on the basis of three tumor markers.

37 d demographic factors associated with use of tumor markers.

38 ing parameters, in conjunction with biologic tumor markers, a novel means of determining prognosis fo

39 s transcription of AFP, an oncodevelopmental tumor marker aberrantly reactivated in hepatoma cells.

40 deposition of high-energy alpha-emitters to tumor markers adjacent to a typical leaky tumor vascular

41 at cooperate to effectively target mSin3A to tumor marker AFP and reestablish transcription repressio

42 easure the concentrations of seven important tumor markers: AFP, ferritin, CEA, hCG-beta, CA 15-3, CA

43 A subset of patients with elevated serum tumor markers after chemotherapy is curable with surgery

44 astatic germ cell cancer with elevated serum tumor markers after first-line (50 patients) or second-l

45 ificance of the rate of decline of the serum tumor marker alpha-fetoprotein (AFP) and human chorionic

46 gion (-850) and core promoter of the hepatic tumor marker alpha-fetoprotein (AFP) gene.

47 e and confer developmental repression of the tumor marker alpha-fetoprotein (AFP).

48 Serum tumor markers alpha-fetoprotein and human chorionic gona

49 The tumor markers also decreased significantly after treatme

50 tissues, and may serve as the best candidate tumor markers among the seven genes studied.

51 These results support the use of PA28 as a tumor marker and a potential target for therapeutic inte

52 gets we identified, we focused on CEACAM5, a tumor marker and facilitator of cell adhesion.

53 vely expressed red fluorescence protein as a tumor marker and green fluorescence protein (GFP) as a r

54 gen (PSA) is considered a uniquely important tumor marker and is broadly used for early detection of

55 onsiderable interest in Gpc3 as a diagnostic tumor marker and its possible role in tumorigenesis.

56 d secondary endpoints included radiological, tumor marker and pathological response to neoadjuvant th

57 UC1 has generated considerable interest as a tumor marker and potential target for tumor killing.

58 erous publications have addressed CD147 as a tumor marker and regulator of cytoskeleton, cell growth,

59 eceptor type alpha (FR-alpha) is a promising tumor marker and target.

60 agents, immune-based therapies, circulating tumor markers and antiangiogenic agents.

61 are derived from tumors because they express tumor markers and are decreased by tumor resection.

62 overall response determined by all imaging, tumor markers and clinical findings at serial follow up.

63 of baseline and follow-up liver function and tumor markers and computed tomographic or magnetic reson

64 indings and immunohistochemical staining for tumor markers and for cytokeratin and mucin proteins wer

65 owerful tool for the identification of novel tumor markers and for the characterization of genetic al

66 New tumor markers and genetic risk factors continue to be di

67 he current use and future potential of novel tumor markers and molecular analysis to characterize cys

68 a minimally invasive system for identifying tumor markers and monitoring drug therapy.

69 mptomatic cervical cancer patients with high tumor markers and negative conventional-imaging findings

70 Surveillance included measurement of serum tumor markers and radiologic imaging at defined interval

71 CR was defined as normalization of serum tumor markers and resolution of radiographic disease (re

72 Serum tumor markers and surgery after chemotherapy have essent

73 ned NOS2 expression and its association with tumor markers and survival in 248 breast tumors.

74 agents, immune-based therapies, circulating tumor markers and targeting agents.

75 ethylation changes hold great promise as DNA tumor markers and their potentially reversible state cre

76 New tumor markers and therapeutic approaches are still neede

77 ing of PD-1, PD-L1, OX40, CD27, TIM3, CD3, a tumor marker, and DAPI.

78 plasma may be useful as a lymphoma-specific tumor marker, and failure to clear clonal Ig DNA may ide

79 inated LCDIO, green fluorescent protein as a tumor marker, and Hoechst 33258 dye as an intravital end

80 relapses were mainly detected by increase in tumor markers, and late relapses were detected by comput

81 Ts inside cells labeled with folate receptor tumor markers, and NIR-triggered cell death, without har

82 rtance of age, tumor site, stage, histology, tumor markers, and treatment regimen and estimate the pe

83 stage [American Joint Committee on Cancer], tumor markers, and treatment).

84 its use as a prognostic or predictive brain tumor marker are now warranted.

85 ns for tumor rebiopsy and use of circulating tumor markers are based on clinical experience and Panel

86 The currently available tumor markers are based on the antigen determination met

87 rthermore, the recent discovery of molecular tumor markers are expected to revolutionize the staging

88 Breast cancer tumor markers are frequently used among women with early

89 Better tumor markers are needed to enable the assignment of met

90 However, universal and highly specific tumor markers are unknown.

91 d colon cancers makes it a significant novel tumor marker as well as a potential therapeutic target.

92 The study examines the role inflammatory and tumor markers as biomarkers to preoperatively predict ou

93 luating the role of pretreatment circulating tumor markers as predictors of prognosis in chemotherapy

94 o assess cardiac surveillance algorithms and tumor markers as prognostic tools.

95 keratins are extensively used as diagnostic tumor markers, as epithelial malignancies largely mainta

96 ivation with VPA suppressed 2 neuroendocrine tumor markers, ASCL1 and chromogranin A.

97 al Oncology guidelines discourage the use of tumor marker assessment for routine surveillance in nonm

98 Of these, 16,653 (42%) received at least one tumor marker assessment, averaging 5.7 tests over 2 year

99 brane antigen (PSMA) is a well-characterized tumor marker associated with prostate cancer and neovasc

100 abilization of disease or decreases in serum tumor markers associated with stable disease in four pat

101 Seven patients had normal tumor markers at initial diagnosis, and none experienced

102 Hence it often fails to detect tumor markers at the early stages of cancer and other di

103 Radiographic or tumor marker-based screening detected six breast cancers

104 rvival was found in patients with increasing tumor markers before surgery compared with patients with

105 lin (MSLN) may be the most "dramatic" of the tumor markers, being strongly overexpressed in nearly on

106 CC) stages I-IV] were assessed for four mRNA tumor markers: beta-human chorionic gonadotropin (beta-h

107 Using mutated MYD88 as a tumor marker, BTK(Cys481) mutations were subclonal, with

108 Alpha-fetoprotein is the most widely used tumor marker, but has poor diagnostic accuracy and ethni

109 the smallest detectable concentration of the tumor marker CA 19-9 and Blue Tongue Viral antibody by o

110 jective tumor response, changes in the serum tumor marker CA 19-9, time to tumor progression (TTP), s

111 he treated patients experienced decreases in tumor marker (CA 19-9) levels of more than 50% from base

112 logic response criteria including changes in tumor marker CA125.

113 RECIST) complete or partial responses and/or tumor marker (CA125) responses, and three (6.0%) maintai

114 NSCLC tumor markers can be detected in histologically negative

115 Tumor markers can facilitate understanding molecular cel

116 simultaneous determination of two different tumor markers, cancer antigen 153 (CA 15-3) and cancer a

117 han those found in serum for the nonspecific tumor markers carbohydrate antigen 19-9 (CA 19-9) and al

118 hy scans, magnetic resonance imaging, and/or tumor markers (carcinoembryonic antigen, CA 15-3, and CA

119 phy scanning, magnetic resonance imaging, or tumor markers (carcinoembryonic antigen, CA 15-3, and CA

120 ce to apoptosis, increased expression of the tumor marker cathepsin L, and a high degree of invasiven

121 function by recognizing the highly expressed tumor marker CD133, which is located on the surface of l

122 we observed that lymphocytes expressing the tumor marker CD30 increased in frequency weeks to months

123 ction of goat IgG and mouse IgG, and for the tumor markers CEA and AFP, were developed.

124 The serum tumor markers CEA, CA125 and CA153 in a 240 mg/kg/d SPG-

125 imaging, cyst fluid cytology, and cyst fluid tumor markers (CEA, CA 72-4, CA 125, CA 19-9, and CA 15-

126 Associations between baseline variables, tumor markers [CEA (carcinoembyronic antigen], CA125, CA

127 Tumor markers (chromogranin A and 5-hydroxyindoleacetic

128 alpha-Fetoprotein (AFP), a tumor marker currently used for the diagnosis and manage

129 MUC16/CA125 is a tumor marker currently used in clinics for the follow-up

130 Patients with slow serum tumor marker decline (alpha-fetoprotein and/or human cho

131 Serum tumor marker decline during chemotherapy was assessed pr

132 by means of objective radiologic response or tumor marker decline was observed in 9 of 11 evaluable p

133 Tumor markers decreased in the majority of patients, and

134 Receiver operator curve analysis of the tumor markers demonstrated that cyst fluid CEA (optimal

135 An assessment of SMAD7 genotypes with tumor markers did not reveal any significant differences

136 geno- and aptasensor for the detection of a tumor marker DNA and a low molecular weight analyte, ade

137 rapy regimens and mAbs directed against ATLL tumor markers do not alter this aggressive clinical cour

138 The study of tumor marker doubling times has guided the extent of sur

139 onstrated single-molecule imaging of a model tumor marker (EGFR) on a panel of living cancer cells.

140 at least among children and adolescents with tumor marker elevation at initial diagnosis.

141 Tumor marker elevation is a highly sensitive method of r

142 se, two had metastatic disease, and four had tumor marker elevation only.

143 basis of whether they were (1) detectable by tumor marker elevation or (2) not detectable by tumor ma

144 ew, 47 of 48 relapses (98%) were detected by tumor marker elevation.

145 tion of affibodies or antibodies against the tumor markers epidermal growth factor receptor (EGFR) an

146 Because breast tumors are heterogeneous in tumor marker expression, we developed a "multimarker" re

147 As a tumor marker for colorectal cancers, carcinoembryonic an

148 ancer tissues, is considered as an important tumor marker for early cancer diagnostics.

149 6%, owing in part to the lack of a reliable tumor marker for early diagnosis.

150 ancers and currently is the best serum-based tumor marker for ovarian cancer.

151 PSCA is a novel tumor marker for pancreatic carcinoma that has potential

152 eases in the prostate specific antigen (PSA) tumor marker for some patients.

153 CA 27.29 was also considered among the serum tumor markers for breast cancer.

154 Six tumor markers for colorectal cancer and eight for breast

155 ll prove useful for the identification of KS tumor markers for diagnosis and as potential drug target

156 are currently no routinely used circulating tumor markers for renal cancer, which is often detected

157 from individual LGL patients can be used as tumor markers for the malignant clone.

158 Multiple imputation was used to impute tumor markers for those missing data on 1-3 markers.

159 ity assessment and response correlation with tumor markers, functional imaging, and RET mutations.

160 us serve as both a diagnostic and prognostic tumor marker; furthermore, it may provide an effective t

161 y of HBx to modify p53 regulation of the HCC tumor marker gene, alpha-fetoprotein (AFP).

162 scription repression of an oncodevelopmental tumor marker gene.

163 ation of the hepatic alpha-fetoprotein (AFP) tumor marker gene.

164 A vast number of tumor markers have been identified and rigorously evalua

165 g proteonomic genome analysis, new candidate tumor markers have been identified but await validation.

166 However, reliable diagnostic or prognostic tumor markers have not been identified for endometrial c

167 Serological tumor markers have proven valuable in the care of indivi

168 Different CRC subtypes, identified based on tumor markers, have been proposed to reflect these pathw

169 These tumor markers, however, are often prone to missing obser

170 Injection site and the tumor markers human epidermal growth factor receptor 2 a

171 The number of tumor markers identified has been exponentially increasi

172 pse was assessed based on case report forms, tumor markers, imaging, and pathology reports.

173 Hematuria was the first tumor marker in a field that has grown to include solubl

174 In addition, the role of hCG as a tumor marker in a variety of cancers has also attracted

175 HER2 is a clinically important tumor marker in breast cancer; however, there is controv

176 ther solid tumors, and it has been used as a tumor marker in molecular detection strategies.

177 Fibrinogen is a potential tumor marker in pancreatic cancer.

178 CA 19-9 is an important tumor marker in patients with pancreatic adenocarcinoma.

179 in primary lung cancer and as a noninvasive tumor marker in plasma and/or serum DNA.

180 r determination of low levels of the VEGF165 tumor marker in serum samples.

181 ptamer at the electrode surface with VEGF165 tumor marker in the sample solution, which results in a

182 pear to have clinical utility as a surrogate tumor marker in the surveillance of TgAb-positive DTC pa

183 ach to an assessment of 779 paired blood and tumor markers in 37 stage III MMel patients, we analyzed

184 g 10 different antibodies and five different tumor markers in a single 50 muL human serum sample.

185 preliminary profiling and identification of tumor markers in biological fluids in several cancer typ

186 e approach for the simultaneous detection of tumor markers in clinical samples.

187 he area of identifying potentially new serum tumor markers in germ cell tumor, as well as the role of

188 In addition, the expression of distinct tumor markers in PDGs was characterized by Muc5ac, S100P

189 Phi and %p2PSA may be useful as tumor markers in predicating patients harboring more agg

190 umor, as well as the role of the traditional tumor markers in predicting outcome to therapy is ongoin

191 This study evaluates a series of tumor markers in pretreatment biopsies from that trial T

192 strategy, the simultaneous detection of two tumor markers in single run carried out.

193 ent of GCTs as well, including the levels of tumor markers in the blood and cerebrospinal fluid that

194 Tumor markers in the serum and cerebrospinal fluid are e

195 es were detected by computed tomography scan/tumor-markers in 87%/3% of seminoma recurrences, in 48%/

196 We examined tumor markers, including PTGS2, phosphorylated AKT, KRAS

197 Analysis of tumor markers indicates that tumor biological difference

198 for performing multianalyte measurements of tumor markers is described.

199 The literature on tumor markers is plagued by nonpublication bias, selecti

200 As an easily accessible tumor marker, it could offer additional useful prognosti

201 art due to the poor performance of available tumor markers leading to delays in diagnosis.

202 heterogeneity of risk factor associations by tumor marker levels while controlling for additional tum

203 postchemotherapy parameters, including serum tumor marker levels, radiology, and pathology at surgica

204 rigenesis and the identification of specific tumor markers may lead to novel strategies for diagnosis

205 inflammatory markers in blood and serologic tumor markers may predict outcomes and are associated wi

206 inearly proportional to the concentration of tumor marker MDM2 in the wide dynamic range of 1pg/ml-1m

207 ination, the quantification of the potential tumor markers microRNA miR-19b and miR-20a is realized w

208 he preparation of variants of the epithelial tumor marker MUC1 carrying one or more Tn, T, or sialyl-

209 us by a either single genetic or biochemical tumor marker (MYCN, DNA, NSE, or ferritin), or by both u

210 nations (n = 30), increased plasma levels of tumor markers (n = 27), or clinical suspicion of recurre

211 on of NET (n = 70), elevated blood levels of tumor markers (n = 49), and image-based suspicion of NET

212 ble genes, including the recently discovered tumor marker NDRG1 (Cap43).

213 with lower lobe cancer had a higher level of tumor markers (neuron-specific enolase and cytokeratin f

214 atients undergoing chemotherapy and elevated tumor markers (odds ratio, 6.05; P = .008) in patients u

215 e have recently identified active Stat5 as a tumor marker of favorable prognosis in human breast canc

216 alpha-fetoprotein (AFP) gene is a diagnostic tumor marker of hepatocellular carcinoma.

217 etween AMP1 and its human homolog HsGCPII, a tumor marker of medical interest.

218 e potential as novel therapeutic targets and tumor markers of pancreatic cancer.

219 We also imaged different surface tumor markers on two live cell lines.

220 characterized them in order to uncover novel tumor markers, oncogenes, and therapeutic targets for HC

221 d imply the potential of AP-2beta as a novel tumor marker or a cancer therapeutic target.

222 We found no association between serum tumor markers or ERCC1 expression with response or survi

223 0.42; 95% CI 0.27-0.64), regardless of other tumor markers or stage, or patient sex or age.

224 nded surveillance regimens using ultrasound, tumor markers or testicular biopsy are too costly and do

225 ctive targets for novel therapeutic targets, tumor markers, or as a means of screening pancreatic can

226 as age, cyst location, mural nodules, serum tumor markers, or bilirubin.

227 icles (iMP) that expressed platelet markers, tumor markers, or both.

228 e than 2 cm, multiple masses, elevated serum tumor markers, or disease outside the primary landing zo

229 due to clinical symptoms, elevated levels of tumor markers, or indeterminate tumors suggestive of NET

230 ith patients with normal and declining serum tumor markers (P =.09).

231 s compared with patients with elevated serum tumor markers (P =.33).

232 actor Receptor 2 (HER2), as a key prognostic tumor marker, plays a critical role in screening, early

233 univariate analysis, all 3 inflammatory and tumor markers predicted for both PFS and OS, respectivel

234 resis' technologies to facilitate tissue and tumor-marker profiling under these circumstances.

235 Reporting recommendations for tumor marker prognostic studies criteria were followed,

236 The REMARK (Reporting Recommendations for Tumor Marker Prognostic Studies) guideline includes a ch

237 ns and REMARK [Reporting Recommendations for Tumor Marker Prognostic Studies] criteria for reporting

238 The tumor marker (PSMA) has been detected in a range of conc

239 ossible that serum IGF-I may be serving as a tumor marker rather than an etiologic factor in prostate

240 Serum tumor markers remained negative.

241 The field of bladder cancer tumor markers remains a rapidly evolving area in which n

242 31% expressed 4, 3, 2, 1, and 0 of the mRNA tumor markers, respectively.

243 ria in Solid Tumors version 1.0, biochemical tumor marker response, overall survival, and safety.

244 Tumor markers should not be the sole criteria for determ

245 There is an urgent need to identify relevant tumor markers showing high sensitivity and specificity f

246 cancer immunotherapeutics with no need for a tumor marker.Significance: Targeted type I interferon el

247 lusion of quality-of-life data and molecular tumor markers, so that this information could be capture

248 ersistent postorchiectomy elevation of serum tumor markers (STM) or clinical stage (CS) IIB disease f

249 Preoperative serum tumor markers (STMs) normalized/decreased in 74% of pati

250 to develop a score based primarily on serum tumor markers (STMs) that could predict short cancer-spe

251 At diagnosis, 43 patients had elevated serum tumor markers (STMs), and 20 had extramediastinal diseas

252 istology, hematological status, serial serum tumor markers (STMs), and STM changes over time.

253 treme use of disease-monitoring tests (serum tumor markers [STMs] and radiographic imaging) among wom

254 er when designing, conducting, and analyzing tumor marker studies and prognostic studies in medicine

255 adherence to higher standards for reporting tumor marker studies.

256 matic reviews and meta-analyses of published tumor marker studies.

257 ms are discussed, including development of a tumor marker study registry, greater attention to assay

258 acquisition is the collection of circulating tumor markers such as cell-free nucleic acids and circul

259 e with serial physical examination and serum tumor markers such as estradiol and inhibin is reasonabl

260 New tumor markers, such as lactate dehydrogenase isoenzyme-1

261 notypically altered in that they express the tumor marker survivin.

262 t express pRb and express the neuroendocrine tumor markers synaptophysin and microtubule-associated p

263 tigen profiling of intact tumors to identify tumor markers targetable with antibodies.

264 Serum tumor marker testing disclosed a slightly elevated alpha

265 ial benefits and harms of surveillance-based tumor marker testing is needed.

266 To update the recommendations for the use of tumor marker tests in the prevention, screening, treatme

267 Our objective was to determine use of tumor marker tests such as carcinoembryonic antigen and

268 ived no abdominal imaging, chest imaging, or tumor marker tests within the first year of diagnosis.

269 Alpha-fetoprotein is a tumor marker that has been used for surveillance and dia

270 Carcinoembryonic antigen (CEA) is a tumor marker that is associated with metastasis, poor re

271 mbrane antigen, a well-known prostate cancer tumor marker that is overexpressed on prostate acinar ep

272 Development of tumor markers that can detect colon cancer at an early s

273 ethod has been tested for the detection of a tumor marker, the Prostate Specific Membrane Antigen (PS

274 ase detection of alpha-fetoprotein, a common tumor marker, the system shows a greater than 200-fold s

275 To date, well-characterized molecular tumor markers to detect occult breast cancer cells in bl

276 Currently, there are no specific tumor markers to determine initial risk or progression t

277 variables could be combined with biological tumor markers to provide a novel means of determining pr

278 ied into 5 subtypes based on combinations of tumor markers: type 1 (microsatellite instability [MSI]-

279 y-stage breast cancer between 2001 and 2007, tumor marker usage within 2 years after diagnosis was id

280 CA 125 is the standard tumor marker used to follow women during or after treatm

281 for monoclonal immunoglobulin as a leukemia tumor marker using a surface plasmon resonance (SPR) bio

282 igen and was capable of measuring a specific tumor marker using electrochemical enzyme-based competit

283 Testing for the NMP22 tumor marker was conducted in a blinded manner.

284 lex detection of three different lung cancer tumor markers was realized.

285 Prechemotherapy levels of serum tumor markers were alpha-fetoprotein (AFP) 2.0 ng/mL, hu

286 d CONCLUSIONS: Thirteen categories of breast tumor markers were considered, six of which were new for

287 None of the tumor markers were expressed in any normal donor bloods.

288 d pathologic staging parameters and biologic tumor markers were investigated to devise the scoring sy

289 ubtypes, defined by combinations of 4 common tumor markers, were associated with differences in survi

290 heterogeneity of risk factors with specific tumor markers when using standard competing-risk surviva

291 eriodically by quantifying serum levels of a tumor marker), whereas tumors grew progressively in mice

292 Moreover, our results are also enriched for tumor markers which are predictive of clinical features

293 sk factor associations according to specific tumor markers while controlling for other markers.

294 results suggest that FAIM2 is a potential NE tumor marker with higher expression in atypical carcinoi

295 wn imaging, 31 patients (64.6%) had abnormal tumor markers with abnormal imaging, and one patient (2.

296 (CIs) for associations of these subtypes and tumor markers with disease-specific survival (DSS) and o

297 Sixty-one candidate tumor markers with expression predicted to be characteri

298 Of the 47 patients, 16 (33.3%) had abnormal tumor markers with normal/unknown imaging, 31 patients (

299 powerful tools for screening and identifying tumor markers with only minute samples.

300 on human prostatic acid phosphatase (PAP), a tumor marker, with a limit of detection of 11 pM and C-r